Skip to main content
SpringerLink
Log in

Uterine Cancer: Pathology

  • Chapter
Uterine Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 567 Accesses

Abstract

Endometrioid adenocarcinoma is the most common type of endometrial carcinoma (approximately 85 %). By definition, it should resemble, at least focally, proliferative-type endometrium with tubular glands lined by mitotically active columnar cells. Common problems in diagnosis involve its distinction from complex atypical hyperplasia, endocervical adenocarcinoma, serous carcinoma, clear cell carcinoma, and carcinosarcoma. Pure serous carcinomas comprise about 10 % of endometrial cancers. The term “serous” refers to shared characteristics with cells lining the fallopian tube, particularly the tumor cells’ columnar shape, eosinophilic cytoplasm, and tendency to form papillae. However, some serous carcinomas are not papillary but glandular. Importantly, all serous carcinomas exhibit marked nuclear pleomorphism and most demonstrate discrepancies between architectural differentiation and cytologic features. Clear cell carcinoma is the third most common endometrial carcinoma subtype, even though it represents <5 % of all endometrial cancers. Epidemiologic characteristics of patients with clear cell carcinoma are obscure because of this tumor’s rarity, difficulties in diagnostic reproducibility, and accumulating evidence that there are perhaps several subtypes of clear cell carcinoma. Most clear cell carcinomas are composed of cells with clear cytoplasm, but this feature is not restricted to clear cell carcinoma and some clear cell carcinomas contain cells with eosinophilic cytoplasm. Other subtypes of endometrial carcinoma are rare and include squamous, transitional, small cell, undifferentiated/dedifferentiated, and mixed cell types. Among pure mesenchymal tumors of the uterus, leiomyosarcoma is the most common. Microscopic criteria to establish the diagnosis of leiomyosarcoma include the combination of two of the following: cytologic atypia, mitotic activity, and tumor cell necrosis. The threshold for mitotic activity varies for spindled, epithelioid, and myxoid subtypes and a variety of uterine tumors enter in the differential diagnosis, including several variants of leiomyoma (mitotically active, apoplectic, with bizarre nuclei, highly cellular, and hydropic). Low-grade endometrial stromal sarcomas are composed of a homogenous population of small cells with scant cytoplasm resembling proliferative-type endometrial stroma. They show a diffuse growth and infiltrate the uterine wall in a permeative (not destructive) fashion and may have prominent intravascular growth. High-grade endometrial stromal sarcomas do not resemble proliferative stroma, are composed of small rounds cells with brisk mitotic activity and are more aggressive than low-grade tumors. Undifferentiated uterine sarcoma is a very poorly differentiated sarcoma and a diagnosis of exclusion. Carcinosarcomas (malignant mixed müllerian tumors) are biphasic tumors typically composed of highly malignant epithelial and stromal/mesenchymal elements. The histogenesis of these tumors has evolved in recent years and it is now accepted that they either arise from a common pluripotential cell with divergent differentiation or that the sarcomatous component develops from the carcinomatous component by a metaplastic process. Other rare low-grade or clinically aggressive mesenchymal tumors include: (1) low-grade müllerian adenosarcoma (composed of benign-appearing glands and malignant stroma); (2) PEComa, which is composed of epithelioid cells that are typically positive for HMB-45 and may be associated with tuberous sclerosis; and (3) intravenous leiomyomatosis which shows a proliferation of smooth muscle cells within vascular spaces. Even though the latter smooth muscle proliferation is considered benign it can behave aggressively from the clinical point of view.

The original version of this chapter was revised. An erratum to this chapter can be found at DOI 10.1007/7631_2018_4

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    CAS  PubMed  Google Scholar 

  2. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

    PubMed  Google Scholar 

  3. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol. 2012;36(5):753–61.

    Google Scholar 

  4. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol. 2005;29(3):295–304.

    PubMed  Google Scholar 

  5. Conlon N, Leitao Jr MM, Abu-Rustum NR, Soslow RA. Grading uterine endometrioid carcinoma: a proposal that binary is best. Am J Surg Pathol. 2014;38(12):1583–7.

    PubMed  Google Scholar 

  6. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24(9):1201–8.

    CAS  PubMed  Google Scholar 

  7. Murray SK, Young RH, Scully RE. Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 Cases of a favorable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol. 2000;8(4):279–89.

    PubMed  Google Scholar 

  8. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol. 2005;29(2):157–66.

    PubMed  Google Scholar 

  9. Quick CM, May T, Horowitz NS, Nucci MR. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012;31(4):337–43.

    PubMed  Google Scholar 

  10. Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23(1):69–78.

    CAS  PubMed  Google Scholar 

  11. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol. 2003;22(4):324–33.

    PubMed  Google Scholar 

  12. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49(12):2547–59.

    CAS  PubMed  Google Scholar 

  13. Longacre TA, Chung MH, Jensen DN, Hendrickson MR. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol. 1995;19(4):371–406.

    CAS  PubMed  Google Scholar 

  14. Norris HJ, Tavassoli FA, Kurman RJ. Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol. 1983;7(8):839–47.

    CAS  PubMed  Google Scholar 

  15. Melhem MF, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol. 1987;6(4):347–55.

    CAS  PubMed  Google Scholar 

  16. Ross JC, Eifel PJ, Cox RS, Kempson RL, Hendrickson MR. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol. 1983;7(8):715–29.

    CAS  PubMed  Google Scholar 

  17. Hendrickson MR, Kempson RL. Ciliated carcinoma--a variant of endometrial adenocarcinoma: a report of 10 cases. Int J Gynecol Pathol. 1983;2(1):1–12.

    CAS  PubMed  Google Scholar 

  18. Tobon H, Watkins GJ. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol. 1985;4(4):328–35.

    CAS  PubMed  Google Scholar 

  19. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol. 1985;4(4):279–88.

    CAS  PubMed  Google Scholar 

  20. Parkash V, Carcangiu ML. Endometrioid endometrial adenocarcinoma with psammoma bodies. Am J Surg Pathol. 1997;21(4):399–406.

    CAS  PubMed  Google Scholar 

  21. Hedrick Ellenson L, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, Hedrick Ellenson L, Ronnett BM, editors. Blaustein’s Pathology of the Female Genital Tract. New York:Springer; 2011. p. 407–8.

    Google Scholar 

  22. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am J Surg Pathol. 1986;10(8):568–76.

    CAS  PubMed  Google Scholar 

  23. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996;27(2):172–7.

    CAS  PubMed  Google Scholar 

  24. Dallenbach-Hellweg G, Lang-Averous G, Hahn U. The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS Suppl. 1991;23:91–9.

    CAS  PubMed  Google Scholar 

  25. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2002;21(1):11–5.

    PubMed  Google Scholar 

  26. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2002;21(1):4–10.

    PubMed  Google Scholar 

  27. Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3(2):99–107.

    Google Scholar 

  28. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002;12(4):372–5.

    CAS  PubMed  Google Scholar 

  29. Cherchi PL, Bosincu L, Dessole S, et al. Immunohistochemical expression of BerEP4, a new epithelial antigen, in endometrial carcinoma: correlation with clinical parameters. Eur J Gynaecol Oncol. 1999;20(5–6):393–5.

    CAS  PubMed  Google Scholar 

  30. Katari RS, Fernsten PD, Schlom J. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res. 1990;50(16):4885–90.

    CAS  PubMed  Google Scholar 

  31. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19(8):1091–100.

    CAS  PubMed  Google Scholar 

  32. Soslow RA, Shen PU, Chung MH, Isacson C, Baergen RN. Cyclin D1 expression in high-grade endometrial carcinomas--association with histologic subtype. Int J Gynecol Pathol. 2000;19(4):329–34.

    CAS  PubMed  Google Scholar 

  33. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814–24.

    CAS  PubMed  Google Scholar 

  34. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26(11):1268–74.

    CAS  PubMed  Google Scholar 

  35. Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J, Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol. 2005;29(10):1322–9.

    PubMed  Google Scholar 

  36. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15(10):1032–7.

    PubMed  Google Scholar 

  37. Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler Jr WC, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11.

    PubMed  Google Scholar 

  38. Geisler JP, Sorosky JI, Duong HL, et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001;83(3):501–3.

    CAS  PubMed  Google Scholar 

  39. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11(3):485–90.

    CAS  PubMed  Google Scholar 

  40. Olson SH, Finstad CL, Harlap S, Kurian L, Saigo PE, Barakat RR. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(10):815–7.

    CAS  PubMed  Google Scholar 

  41. Parkash V, Carcangiu ML. Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix. Cancer. 1992;69(2):496–501.

    CAS  PubMed  Google Scholar 

  42. Pothuri B, Ramondetta L, Martino M, et al. Development of endometrial cancer after radiation treatment for cervical carcinoma. Obstet Gynecol. 2003;101(5 Pt 1):941–5.

    PubMed  Google Scholar 

  43. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47(3):298–305.

    CAS  PubMed  Google Scholar 

  44. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108.

    CAS  PubMed  Google Scholar 

  45. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26(11):1260–7.

    CAS  PubMed  Google Scholar 

  46. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19(4):417–32.

    CAS  PubMed  Google Scholar 

  47. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28(12):1568–78.

    PubMed  Google Scholar 

  48. Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol. 1999;18(3):233–7.

    CAS  PubMed  Google Scholar 

  49. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150(1):177–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 2004;17(5):530–7.

    CAS  PubMed  Google Scholar 

  51. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29(6):551–8.

    CAS  PubMed  Google Scholar 

  52. Carcangiu ML, Dorji T, Radice P, Bertario L, Sala P. HNPCC-related endometrial carcinomas show a high frequency of non-endometrioid types and of high FIGO grade endometrioid carcinomas. Mod Pathol. 2006;19(1S):173A.

    Google Scholar 

  53. Vang R, Whitaker BP, Farhood AI, Silva EG, Ro JY, Deavers MT. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol. 2001;20(3):252–9.

    CAS  PubMed  Google Scholar 

  54. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38(2):189–96.

    PubMed  Google Scholar 

  55. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20(6):580–7.

    CAS  PubMed  Google Scholar 

  56. Zaino R, Carinelli SG, Ellenson LH, et al. Epithelial tumours and precursors. Chapter 5, Tumours of the uterine corpus. In: Kurman R, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. Lyon: IARC Press; 2014. p. 125–35.

    Google Scholar 

  57. Goodman A, Zukerberg LR, Rice LW, Fuller AF, Young RH, Scully RE. Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol. 1996;61(1):54–60.

    CAS  PubMed  Google Scholar 

  58. Lininger RA, Ashfaq R, Albores-Saavedra J, Tavassoli FA. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer. 1997;79(10):1933–43.

    CAS  PubMed  Google Scholar 

  59. Spiegel GW, Austin RM, Gelven PL. Transitional cell carcinoma of the endometrium. Gynecol Oncol. 1996;60(2):325–30.

    CAS  PubMed  Google Scholar 

  60. Abeler VM, Kjorstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer. 1991;68(1):98–105.

    CAS  PubMed  Google Scholar 

  61. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316–21.

    PubMed  Google Scholar 

  62. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30.

    CAS  PubMed  Google Scholar 

  63. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76(3):399–402.

    CAS  PubMed  Google Scholar 

  64. Schwartz PE, Kelly MG. Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am. 2006;33(1):183–98. xii.

    PubMed  Google Scholar 

  65. Mittal KR, Chen F, Wei JJ, et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol. 2009;22(10):1303–11.

    CAS  PubMed  Google Scholar 

  66. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98(6):3387–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Rammeh-Rommani S, Mokni M, Stita W, et al. [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases]. J Gynecol Obstet Biol Reprod (Paris). 2005;34(6):568–71.

    CAS  Google Scholar 

  68. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol. 1993;168(1 Pt 1):180–3.

    CAS  PubMed  Google Scholar 

  69. Oliva ECP, Young RH. Mesenchymal tumors of the uterus: selected topics emphasizing potential pitfalls. Curr Diagn Pathol. 2002;8:268–82.

    Google Scholar 

  70. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535–58.

    CAS  PubMed  Google Scholar 

  71. Chiang S, Oliva E. Recent developments in uterine mesenchymal neoplasms. Histopathology. 2013;62(1):124–37.

    PubMed  Google Scholar 

  72. Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol. 2013;37(5):650–8.

    PubMed  Google Scholar 

  73. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30(1):83–9.

    PubMed  Google Scholar 

  74. Veras E, Malpica A, Deavers MT, Silva EG. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol. 2009;28(4):316–21.

    PubMed  Google Scholar 

  75. Hornick JL, Fletcher CD. Criteria for malignancy in nonvisceral smooth muscle tumors. Ann Diagn Pathol. 2003;7(1):60–6.

    PubMed  Google Scholar 

  76. Veras E, Zivanovic O, Jacks L, Chiappetta D, Hensley M, Soslow R. “Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol. 2011;35(11):1626–37.

    PubMed  Google Scholar 

  77. Tavassoli F. World Health Organization classification of tumours. In: Tavassoli F, Devilee P, editors. Pathology and genetics of tumors of breast and female genital organs. Lyon: IARC Press; 2003.

    Google Scholar 

  78. Burns B, Curry RH, Bell ME. Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases. Am J Obstet Gynecol. 1979;135(1):109–14.

    CAS  PubMed  Google Scholar 

  79. Coard KC, Fletcher HM. Leiomyosarcoma of the uterus with a florid intravascular component (“intravenous leiomyosarcomatosis”). Int J Gynecol Pathol. 2002;21(2):182–5.

    PubMed  Google Scholar 

  80. Kurman RJ, Norris HJ. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases. Cancer. 1976;37(4):1853–65.

    CAS  PubMed  Google Scholar 

  81. Prayson RA, Goldblum JR, Hart WR. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. Am J Surg Pathol. 1997;21(4):383–91.

    CAS  PubMed  Google Scholar 

  82. Oliva E, Nielsen GP, Clement PB, et al. Epithelioid smooth muscle tumors of the uterus: a clinicopathologic analysis of 80 cases. Mod Pathol. 1997;10:107A.

    Google Scholar 

  83. Atkins K, Bell SW, Kempson RL. Myxoid smooth muscle tumors of the uterus. Mod Pathol. 2001;14:132A.

    Google Scholar 

  84. Burch DM, Tavassoli FA. Myxoid leiomyosarcoma of the uterus. Histopathology. 2011;59(6):1144–55.

    PubMed  Google Scholar 

  85. Chen KT. Myxoid leiomyosarcoma of the uterus. Int J Gynecol Pathol. 1984;3(4):389–92.

    CAS  PubMed  Google Scholar 

  86. King ME, Dickersin GR, Scully RE. Myxoid leiomyosarcoma of the uterus. A report of six cases. Am J Surg Pathol. 1982;6(7):589–98.

    CAS  PubMed  Google Scholar 

  87. Pounder DJ, Iyer PV. Uterine leiomyosarcoma with myxoid stroma. Arch Pathol Lab Med. 1985;109(8):762–4.

    CAS  PubMed  Google Scholar 

  88. Salm R, Evans DJ. Myxoid leiomyosarcoma. Histopathology. 1985;9(2):159–69.

    CAS  PubMed  Google Scholar 

  89. Oliva E, Young RH, Amin MB, Clement PB. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002;26(4):403–12.

    PubMed  Google Scholar 

  90. Loddenkemper C, Mechsner S, Foss HD, et al. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma. Am J Surg Pathol. 2003;27(11):1458–62.

    PubMed  Google Scholar 

  91. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004;101(6):1455–62.

    CAS  PubMed  Google Scholar 

  92. Iwata J, Fletcher CD. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int. 2000;50(1):7–14.

    CAS  PubMed  Google Scholar 

  93. Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer. 2006;16(2):849–53.

    CAS  PubMed  Google Scholar 

  94. Leath 3rd CA, Straughn Jr JM, Conner MG, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med. 2004;49(2):71–5.

    PubMed  Google Scholar 

  95. Raspollini MR, Pinzani P, Simi L, et al. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol Oncol. 2005;98(2):334–5.

    PubMed  Google Scholar 

  96. Mills AM, Ly A, Balzer BL, et al. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol. 2013;37(5):634–42.

    PubMed  Google Scholar 

  97. D'Angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 2011;121(2):328–33.

    CAS  PubMed  Google Scholar 

  98. Bertsch E, Qiang W, Zhang Q, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014;27(8):1144–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Matsubara A, Sekine S, Yoshida M, et al. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology. 2013;62(4):657–61.

    PubMed  Google Scholar 

  100. Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol. 2014;45(1):65–70.

    CAS  PubMed  Google Scholar 

  101. Perrone T, Dehner LP. Prognostically favorable “mitotically active” smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am J Surg Pathol. 1988;12(1):1–8.

    CAS  PubMed  Google Scholar 

  102. Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol. 1992;97(1):14–20.

    CAS  PubMed  Google Scholar 

  103. Myles JL, Hart WR. Apoplectic leiomyomas of the uterus. A clinicopathologic study of five distinctive hemorrhagic leiomyomas associated with oral contraceptive usage. Am J Surg Pathol. 1985;9(11):798–805.

    CAS  PubMed  Google Scholar 

  104. Norris HJ, Hilliard GD, Irey NS. Hemorrhagic cellular leiomyomas (“apoplectic leiomyoma”) of the uterus associated with pregnancy and oral contraceptives. Int J Gynecol Pathol. 1988;7(3):212–24.

    CAS  PubMed  Google Scholar 

  105. Lim D, Ip PP, Cheung AN, Kiyokawa T, Oliva E. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change and clear cell carcinoma. Am J Surg Pathol. 2015;39:1061–9.

    PubMed  Google Scholar 

  106. Croce S, Young RH, Oliva E. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol. 2014;38(10):1330–9.

    PubMed  Google Scholar 

  107. Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol. 1997;21(11):1261–70.

    CAS  PubMed  Google Scholar 

  108. McCluggage WG, Lioe TF, McClelland HR, Lamki H. Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer. 2002;12(1):128–32.

    PubMed  Google Scholar 

  109. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32(8):1228–38.

    PubMed  Google Scholar 

  110. Baergen RN, Rutgers JL, Young RH, Osann K, Scully RE. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol. 2006;100(3):511–20.

    PubMed  Google Scholar 

  111. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005;29(12):1558–75.

    PubMed  Google Scholar 

  112. Schoolmeester JK, Howitt BE, Hirsch MS, Dal Cin P, Quade BJ, Nucci MR. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol. 2014;38(2):176–88.

    PubMed  Google Scholar 

  113.  Vang R, Kempson RL. Perivascular epithelioid cell tumor (‘PEComa’) of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol. 2002;26(1):1–13.

    PubMed  Google Scholar 

  114.  Clement PB, Scully RE. Uterine tumors resembling ovarian sex-cord tumors. A clinicopathologic analysis of fourteen cases. Am J Clin Pathol. 1976;66(3):512–25.

    CAS  PubMed  Google Scholar 

  115.  Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol. 2006;19(1):17–24.

    CAS  PubMed  Google Scholar 

  116.  Krishnamurthy S, Jungbluth AA, Busam KJ, Rosai J. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. Am J Surg Pathol. 1998;22(9):1078–82.

    CAS  PubMed  Google Scholar 

  117.  Nielsen GP, Oliva E, Young RH, Rosenberg AE, Dickersin GR, Scully RE. Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Int J Gynecol Pathol. 1995;14(4):283–92.

    CAS  PubMed  Google Scholar 

  118.  Roma AA, Yang B, Senior ME, Goldblum JR. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol. 2005;24(2):131–5.

    PubMed  Google Scholar 

  119.  Giordano G, Gnetti L, Ricci R, Merisio C, Melpignano M. Metastatic extragenital neoplasms to the uterus: a clinicopathologic study of four cases. Int J Gynecol Cancer. 2006;16 Suppl 1:433–8.

    PubMed  Google Scholar 

  120. Clement PB, Young RH, Scully RE. Diffuse, perinodular, and other patterns of hydropic degeneration within and adjacent to uterine leiomyomas. Problems in differential diagnosis. Am J Surg Pathol. 1992;16(1):26–32.

    CAS  PubMed  Google Scholar 

  121. Parra-Herran C et al. Am J Surg Pathol 2015; 39:157–68

    Google Scholar 

  122.  Oliva E, Carcangiu ML, Carinelli S, et al. Mesenchymal tumours. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. Lyon: IARC Press; 2014. p. 135–47.

    Google Scholar 

  123.  Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14(5):415–38.

    CAS  PubMed  Google Scholar 

  124.  Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7(5):257–81.

    CAS  PubMed  Google Scholar 

  125.  Oliva E, Clement PB, Young RH, Scully RE. Mixed endometrial stromal and smooth muscle tumors of the uterus: a clinicopathologic study of 15 cases. Am J Surg Pathol. 1998;22(8):997–1005.

    CAS  PubMed  Google Scholar 

  126.  Baker PM, Moch H, Oliva E. Unusual morphologic features of endometrial stromal tumors: a report of 2 cases. Am J Surg Pathol. 2005;29(10):1394–8.

    PubMed  Google Scholar 

  127. Oliva E, Young RH, Clement PB, Scully RE. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol. 1999;18(4):310–9.

    CAS  PubMed  Google Scholar 

  128. Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002;26(9):1142–50.

    PubMed  Google Scholar 

  129. Clement PB, Scully RE. Endometrial stromal sarcomas of the uterus with extensive endometrioid glandular differentiation: a report of three cases that caused problems in differential diagnosis. Int J Gynecol Pathol. 1992;11(3):163–73.

    CAS  PubMed  Google Scholar 

  130. Levine PH, Abou-Nassar S, Mittal K. Extrauterine low-grade endometrial stromal sarcoma with florid endometrioid glandular differentiation. Int J Gynecol Pathol. 2001;20(4):395–8.

    CAS  PubMed  Google Scholar 

  131. McCluggage WG, Date A, Bharucha H, Toner PG. Endometrial stromal sarcoma with sex cord-like areas and focal rhabdoid differentiation. Histopathology. 1996;29(4):369–74.

    CAS  PubMed  Google Scholar 

  132. Lifschitz-Mercer B, Czernobilsky B, Dgani R, Dallenbach-Hellweg G, Moll R, Franke WW. Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer. 1987;59(8):1494–9.

    CAS  PubMed  Google Scholar 

  133. Oliva E, Clement PB, Young RH. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors. Int J Gynecol Pathol. 2002;21(1):48–55.

    PubMed  Google Scholar 

  134. Kim YH, Cho H, Kyeom-Kim H, Kim I. Uterine endometrial stromal sarcoma with rhabdoid and smooth muscle differentiation. J Korean Med Sci. 1996;11(1):88–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Fadare O, McCalip B, Mariappan MR, Hileeto D, Parkash V. An endometrial stromal tumor with osteoclast-like giant cells. Ann Diagn Pathol. 2005;9(3):160–5.

    PubMed  Google Scholar 

  136. McCluggage WG, Young RH. Endometrial stromal sarcomas with true papillae and pseudopapillae. Int J Gynecol Pathol. 2008;27(4):555–61.

    PubMed  Google Scholar 

  137. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113(3):374–82.

    CAS  PubMed  Google Scholar 

  138. Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol. 1991;22(3):224–30.

    CAS  PubMed  Google Scholar 

  139. Lillemoe TJ, Perrone T, Norris HJ, Dehner LP. Myogenous phenotype of epithelial-like areas in endometrial stromal sarcomas. Arch Pathol Lab Med. 1991;115(3):215–9.

    CAS  PubMed  Google Scholar 

  140. Wu TI, Chou HH, Yeh CJ, et al. Clinicopathologic parameters and immunohistochemical study of endometrial stromal sarcomas. Int J Gynecol Pathol. 2013;32(5):482–92.

    CAS  PubMed  Google Scholar 

  141. Moinfar F, Regitnig P, Tabrizi AD, Denk H, Tavassoli FA. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch. 2004;444(5):410–4.

    CAS  PubMed  Google Scholar 

  142. de Leval L, Waltregny D, Boniver J, Young RH, Castronovo V, Oliva E. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. Am J Surg Pathol. 2006;30(3):319–27.

    PubMed  Google Scholar 

  143. Franquemont DW, Frierson Jr HF, Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol. 1991;15(9):861–70.

    CAS  PubMed  Google Scholar 

  144. Rush DS, Tan J, Baergen RN, Soslow RA. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol. 2001;25(2):253–8.

    CAS  PubMed  Google Scholar 

  145. Baker RJ, Hildebrandt RH, Rouse RV, Hendrickson MR, Longacre TA. Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements. Hum Pathol. 1999;30(6):671–9.

    CAS  PubMed  Google Scholar 

  146. Sumathi VP, Al-Hussaini M, Connolly LE, Fullerton L, McCluggage WG. Endometrial stromal neoplasms are immunoreactive with WT-1 antibody. Int J Gynecol Pathol. 2004;23(3):241–7.

    CAS  PubMed  Google Scholar 

  147. Geller MA, Argenta P, Bradley W, et al. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol. 2004;95(3):632–6.

    CAS  PubMed  Google Scholar 

  148. Hrzenjak A, Tippl M, Kremser ML, et al. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol. 2004;204(1):19–27.

    CAS  PubMed  Google Scholar 

  149. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2004;17(1):104–8.

    PubMed  Google Scholar 

  150. Chiang S, Oliva E. Cytogenetic and molecular aberrations in endometrial stromal tumors. Hum Pathol. 2011;42(5):609–17.

    CAS  PubMed  Google Scholar 

  151. Sandberg AA. The cytogenetics and molecular biology of endometrial stromal sarcoma. Cytogenet Genome Res. 2007;118(2–4):182–9.

    CAS  PubMed  Google Scholar 

  152. Dionigi A, Oliva E, Clement PB, Young RH. Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2002;26(5):567–81.

    PubMed  Google Scholar 

  153. Oliva E. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol. 2014;33(4):374–84.

    CAS  PubMed  Google Scholar 

  154. Oliva E, Young RH, Clement PB, Bhan AK, Scully RE. Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol. 1995;19(7):757–68.

    CAS  PubMed  Google Scholar 

  155. Goldblum JR, Clement PB, Hart WR. Adenomyosis with sparse glands. A potential mimic of low-grade endometrial stromal sarcoma. Am J Clin Pathol. 1995;103(2):218–23.

    CAS  PubMed  Google Scholar 

  156. Clement PB. Intravenous leiomyomatosis of the uterus. Pathol Annu. 1988;23(Pt 2):153–83.

    PubMed  Google Scholar 

  157. Gilks CB, Clement PB, Hart WR, Young RH. Uterine adenomyomas excluding atypical polypoid adenomyomas and adenomyomas of endocervical type: a clinicopathologic study of 30 cases of an underemphasized lesion that may cause diagnostic problems with brief consideration of adenomyomas of other female genital tract sites. Int J Gynecol Pathol. 2000;19(3):195–205.

    CAS  PubMed  Google Scholar 

  158. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81.

    CAS  PubMed  Google Scholar 

  159. Lee CH, Marino-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.

    PubMed  Google Scholar 

  160. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl):1702–9.

    CAS  PubMed  Google Scholar 

  161. Clement PB, Oliva E, Young RH. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol. 1996;15(3):222–9.

    CAS  PubMed  Google Scholar 

  162. Clarke BA, Mulligan AM, Irving JA, McCluggage WG, Oliva E. Mullerian adenosarcomas with unusual growth patterns: staging issues. Int J Gynecol Pathol. 2011;30(4):340–7.

    PubMed  Google Scholar 

  163. Howitt BE, Quade BJ, Nucci MR. Uterine polyps with features overlapping with those of Mullerian adenosarcoma: a clinicopathologic analysis of 29 cases emphasizing their likely benign nature. Am J Surg Pathol. 2015;39(1):116–26.

    PubMed  Google Scholar 

  164. Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol. 2009;33(2):278–88.

    PubMed  Google Scholar 

  165. Clement PB, Scully RE. Mullerian adenosarcomas of the uterus with sex cord-like elements. A clinicopathologic analysis of eight cases. Am J Clin Pathol. 1989;91(6):664–72.

    CAS  PubMed  Google Scholar 

  166. Ramos P, Ruiz A, Carabias E, Pinero I, Garzon A, Alvarez I. Mullerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature. Gynecol Oncol. 2002;84(1):161–6.

    CAS  PubMed  Google Scholar 

  167. Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol. 1989;13(1):28–38.

    CAS  PubMed  Google Scholar 

  168. Wu RI, Schorge JO, Dal Cin P, Young RH, Oliva E. Mullerian adenosarcoma of the uterus with low-grade sarcomatous overgrowth characterized by prominent hydropic change resulting in mimicry of a smooth muscle tumor. Int J Gynecol Pathol. 2014;33(6):573–80.

    PubMed  Google Scholar 

  169. Soslow RA, Ali A, Oliva E. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32(7):1013–21.

    PubMed  Google Scholar 

  170. Howitt BE, Sholl LM, Dal Cin P, et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol. 2015;235(1):37–49.

    CAS  PubMed  Google Scholar 

  171. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204–8.

    PubMed  Google Scholar 

  172. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 2002;55(5):321–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  173. Zelmanowicz A, Hildesheim A, Sherman ME, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol. 1998;69(3):253–7.

    CAS  PubMed  Google Scholar 

  174. Costa MJ, Khan R, Judd R. Carcinoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Arch Pathol Lab Med. 1991;115(6):583–90.

    CAS  PubMed  Google Scholar 

  175. Grayson W, Taylor LF, Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol. 2001;25(3):338–47.

    CAS  PubMed  Google Scholar 

  176. Clement PB, Zubovits JT, Young RH, Scully RE. Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol. 1998;17(3):211–22.

    CAS  PubMed  Google Scholar 

  177. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31(11):1653–61.

    PubMed  Google Scholar 

  178. Fukunaga M, Nomura K, Endo Y, Ushigome S, Aizawa S. Carcinosarcoma of the uterus with extensive neuroectodermal differentiation. Histopathology. 1996;29(6):565–70.

    CAS  PubMed  Google Scholar 

  179. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed Mullerian tumors of the uterus. Mod Pathol. 2000;13(3):328–42.

    CAS  PubMed  Google Scholar 

  180. George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol. 1991;22(3):215–23.

    CAS  PubMed  Google Scholar 

  181. Meis JM, Lawrence WD. The immunohistochemical profile of malignant mixed mullerian tumor. Overlap with endometrial adenocarcinoma. Am J Clin Pathol. 1990;94(1):1–7.

    CAS  PubMed  Google Scholar 

  182. Castilla MA, Moreno-Bueno G, Romero-Perez L, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223(1):72–80.

    CAS  PubMed  Google Scholar 

  183. Pea M, Martignoni G, Zamboni G, Bonetti F. Perivascular epithelioid cell. Am J Surg Pathol. 1996;20(9):1149–53.

    CAS  PubMed  Google Scholar 

  184. Conlon N, Soslow RA, Murali R. Perivascular epithelioid tumours (PEComas) of the gynaecological tract. J Clin Pathol. 2015;68(6):418–26.

    PubMed  PubMed Central  Google Scholar 

  185. Bonetti F, Pea M, Martignoni G, et al. Clear cell (“sugar”) tumor of the lung is a lesion strictly related to angiomyolipoma--the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 1994;26(3):230–6.

    CAS  PubMed  Google Scholar 

  186. Folpe AL, Goodman ZD, Ishak KG, et al. Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults. Am J Surg Pathol. 2000;24(9):1239–46.

    CAS  PubMed  Google Scholar 

  187. Pea M, Bonetti F, Zamboni G, et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology. 1991;23(3):185–8.

    CAS  PubMed  Google Scholar 

  188. Zamboni G, Pea M, Martignoni G, et al. Clear cell “sugar” tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol. 1996;20(6):722–30.

    CAS  PubMed  Google Scholar 

  189. Schoolmeester JK, Dao LN, Sukov WR, et al. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. 2015;39(3):394–404.

    PubMed  PubMed Central  Google Scholar 

  190. Fukunaga M. Perivascular epithelioid cell tumor of the uterus: report of four cases. Int J Gynecol Pathol. 2005;24(4):341–6.

    PubMed  Google Scholar 

  191. Bosincu L, Rocca PC, Martignoni G, et al. Perivascular epithelioid cell (PEC) tumors of the uterus: a clinicopathologic study of two cases with aggressive features. Mod Pathol. 2005;18(10):1336–42.

    PubMed  Google Scholar 

  192. Fang CL, Lin YH, Chen WY. Microscopic endometrial perivascular epithelioid cell nodules: a case report with the earliest presentation of a uterine perivascular epithelioid cell tumor. Diagn Pathol. 2012;7:117.

    PubMed  PubMed Central  Google Scholar 

  193. Froio E, Piana S, Cavazza A, Valli R, Abrate M, Gardini G. Multifocal PEComa (PEComatosis) of the female genital tract associated with endometriosis, diffuse adenomyosis, and endometrial atypical hyperplasia. Int J Surg Pathol. 2008;16(4):443–6.

    PubMed  Google Scholar 

  194. Liang SX, Pearl M, Liu J, Hwang S, Tornos C. “Malignant” uterine perivascular epithelioid cell tumor, pelvic lymph node lymphangioleiomyomatosis, and gynecological pecomatosis in a patient with tuberous sclerosis: a case report and review of the literature. Int J Gynecol Pathol. 2008;27(1):86–90.

    PubMed  Google Scholar 

  195. Lim GS, Oliva E. The morphologic spectrum of uterine PEC-cell associated tumors in a patient with tuberous sclerosis. Int J Gynecol Pathol. 2011;30(2):121–8.

    PubMed  Google Scholar 

  196. Burke M, Opeskin K. Death due to intravenous leiomyomatosis extending to the right pulmonary artery. Pathology. 2004;36(2):202–3.

    PubMed  Google Scholar 

  197. Carr RJ, Hui P, Buza N. Intravenous leiomyomatosis revisited: an experience of 14 cases at a single medical center. Int J Gynecol Pathol. 2015;34(2):169–76.

    PubMed  Google Scholar 

  198. To WW, Ngan HY, Collins RJ. Intravenous leiomyomatosis with intracardiac involvement. Int J Gynaecol Obstet. 1993;42(1):37–40.

    CAS  PubMed  Google Scholar 

  199. Topcuoglu MS, Yaliniz H, Poyrazoglu H, et al. Intravenous leiomyomatosis extending into the right ventricle after subtotal hysterectomy. Ann Thorac Surg. 2004;78(1):330–2.

    PubMed  Google Scholar 

  200. Virzi G, Ragazzi S, Bussichella F, et al. Intravenous leiomyomatosis extending from the inferior caval vein to the pulmonary artery. J Thorac Cardiovasc Surg. 2007;133(3):831–2.

    PubMed  Google Scholar 

  201. Mulvany NJ, Slavin JL, Ostor AG, Fortune DW. Intravenous leiomyomatosis of the uterus: a clinicopathologic study of 22 cases. Int J Gynecol Pathol. 1994;13(1):1–9.

    CAS  PubMed  Google Scholar 

  202. Nogales FF, Navarro N, Martinez de Victoria JM, et al. Uterine intravascular leiomyomatosis: an update and report of seven cases. Int J Gynecol Pathol. 1987;6(4):331–9.

    CAS  PubMed  Google Scholar 

  203. Norris HJ, Parmley T. Mesenchymal tumors of the uterus. V. Intravenous leiomyomatosis. A clinical and pathologic study of 14 cases. Cancer. 1975;36(6):2164–78.

    CAS  PubMed  Google Scholar 

  204. Clement PB, Young RH, Scully RE. Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features. Am J Surg Pathol. 1988;12(12):932–45.

    CAS  PubMed  Google Scholar 

  205. Han HS, Park IA, Kim SH, Lee HP. The clear cell variant of epithelioid intravenous leiomyomatosis of the uterus: report of a case. Pathol Int. 1998;48(11):892–6.

    CAS  PubMed  Google Scholar 

  206. Jordan LB, Al-Nafussi A, Beattie G. Cotyledonoid hydropic intravenous leiomyomatosis: a new variant leiomyoma. Histopathology. 2002;40(3):245–52.

    CAS  PubMed  Google Scholar 

  207. Buza N, Xu F, Wu W, Carr RJ, Li P, Hui P. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Hum Pathol. 2014;45(9):1885–92.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Robert A. Soslow

  2. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    Esther Oliva (Professor of Pathology)

  3. Harvard Medical School, Boston, MA, USA

    Esther Oliva (Professor of Pathology)

Authors
  1. Robert A. Soslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esther Oliva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Oliva .

Editor information

Editors and Affiliations

  1. NYU Langone Medical Center, New York, NY, USA

    Franco Muggia

  2. Division of Gynecologic Oncology, Yale University, Yale School of Medicine, New Haven, CT, USA

    Alessandro D. Santin

  3. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    Esther Oliva (Professor of Pathology) (Professor of Pathology)

  4. Harvard Medical School, Boston, MA, USA

    Esther Oliva (Professor of Pathology) (Professor of Pathology)

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Soslow, R.A., Oliva, E. (2015). Uterine Cancer: Pathology. In: Muggia, F., Santin, A.D., Oliva, E. (eds) Uterine Cancer. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/7631_2015_7

Download citation

  • DOI: https://doi.org/10.1007/7631_2015_7

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-47267-6

  • Online ISBN: 978-3-319-47269-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation